Literature DB >> 31514794

An 82-year-old man with recurrent angioedema.

Charles F Schuler1, Elisabeth A Pedersen2, Marc S McMorris1.   

Abstract

Angioedema is a potentially life-threatening swelling condition that can occur either in isolation or in the context of other syndromes, e.g., anaphylaxis. Angioedema is typically asymmetric, lasts for hours to days, is not gravity dependent, and is often nonpitting. Recurrent angioedema is typically associated with histaminergic and bradykinin-mediated causes, some of which can indicate underlying etiologies with high morbidity or mortality. The differential diagnosis for acute angioedema can include anaphylaxis, chronic urticaria with angioedema, medications such as angiotensin-converting-enzyme inhibitors, hereditary C1 esterase inhibitor defects, and acquired defects; however, the cause is often idiopathic, and effective therapy can be elusive. In this article, we described a unique etiology of a case of isolated recurrent angioedema that improved when the possible underlying cause was successfully treated.

Entities:  

Mesh:

Year:  2019        PMID: 31514794      PMCID: PMC8242989          DOI: 10.2500/aap.2019.40.4242

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  17 in total

1.  Chronic urticaria/angioedema and Graves' disease: Coexistence of 2 antireceptor antibody-mediated diseases.

Authors:  C Irani; N D Gordon; B Zweiman; A I Levinson
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

Review 2.  Superior vena cava syndrome in thoracic malignancies.

Authors:  Philipp M Lepper; Sebastian R Ott; Hanno Hoppe; Christian Schumann; Uz Stammberger; Antonio Bugalho; Steffen Frese; Michael Schmücking; Norbert M Blumstein; Nicolas Diehm; Robert Bals; Jürg Hamacher
Journal:  Respir Care       Date:  2011-01-27       Impact factor: 2.258

Review 3.  Graves' Disease.

Authors:  Terry J Smith; Laszlo Hegedüs
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

4.  Hereditary angioedema and Graves' disease: The first case report.

Authors:  Ming-Jer Liu; Shyh-Dar Shyur; Hsin-Hui Chuang; Ping-Hsien Yang
Journal:  J Formos Med Assoc       Date:  2017-05-26       Impact factor: 3.282

5.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group.

Authors:  M Cicardi; W Aberer; A Banerji; M Bas; J A Bernstein; K Bork; T Caballero; H Farkas; A Grumach; A P Kaplan; M A Riedl; M Triggiani; A Zanichelli; B Zuraw
Journal:  Allergy       Date:  2014-03-27       Impact factor: 13.146

Review 6.  Urticaria and thyroid autoimmunity.

Authors:  Marcello Bagnasco; Paola L Minciullo; Giovanna S Saraceno; Sebastiano Gangemi; Salvatore Benvenga
Journal:  Thyroid       Date:  2011-04       Impact factor: 6.568

7.  Episodic angioedema associated with eosinophilia.

Authors:  G J Gleich; A L Schroeter; J P Marcoux; M I Sachs; E J O'Connell; P F Kohler
Journal:  N Engl J Med       Date:  1984-06-21       Impact factor: 91.245

Review 8.  Chronic idiopathic urticaria and Graves' disease.

Authors:  R M Ruggeri; S Imbesi; S Saitta; A Campennì; S Cannavò; F Trimarchi; S Gangemi
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

Review 9.  Angioedema Phenotypes: Disease Expression and Classification.

Authors:  Maddalena Alessandra Wu; Francesca Perego; Andrea Zanichelli; Marco Cicardi
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 10.  Angioedema in the emergency department: an evidence-based review.

Authors:  R Gentry Wilkerson
Journal:  Emerg Med Pract       Date:  2012-10-20
View more
  2 in total

1.  The continuing "1000 faces of asthma".

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2020-05-01       Impact factor: 2.587

2.  Peanuta non grata revisited.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2019-09-01       Impact factor: 2.587

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.